Helicobacter pylori treatment: New perspectives using current experience.

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori infection is a primary cause of duodenal/gastric ulcers and gastric adenocarcinoma.
• Successful eradication of H. pylori significantly reduces the risk of these associated diseases.
• Current standard triple therapy (amoxicillin, clarithromycin, PPI) shows declining efficacy, with failure rates approaching 32%.

Purpose of the Study:

• To provide an overview of the current status of H. pylori treatment.
• To design an optimal strategy for managing H. pylori infections.
• To address the increasing challenge of H. pylori therapeutic defeat due to antibiotic resistance.

Main Methods:

• Review of current clinical guidelines and treatment approaches for H. pylori.
• Analysis of the impact of antibiotic resistance on treatment efficacy.
• Exploration of novel therapeutic strategies, including probiotics, alternative medicines, and vaccines.

Main Results:

• Standard triple therapy is becoming increasingly ineffective against H. pylori.
• Rising antibiotic resistance necessitates the development of alternative treatment approaches.
• A combination of existing and novel strategies may be required for successful eradication.

Conclusions:

• Clinicians must consider all available alternatives for H. pylori eradication due to treatment failures.
• Development of new preventive vaccines and non-traditional therapies is a promising direction.
• Optimal H. pylori management requires adapting to increasing antibiotic resistance and exploring diverse treatment options.